| Symbollon is a specialty
pharmaceutical company focused on the development and commercialization
of proprietary drugs based on its I2 technology.
I2 is the chemical symbol for molecular iodine. Molecular iodine
is the active species of iodine, a proven fast acting, broad-spectrum
antimicrobial and therapeutic. Formed in 1986, Symbollon completed
its initial public offering in December 1993. Since that time we
have pursued product applications for our technology in two distinct
areas; women’s healthcare and antimicrobial applications.
In female health, Symbollon has developed a proprietary oral tablet
based on our technology that generates I2 in situ (the stomach of
the patient). We refer to this drug as IoGen. In 2000, Symbollon
completed Phase I and II clinical trials evaluating IoGen as a potential
treatment for fibrocystic breast disease. Phase III pivotal trials
will be conducted in 2005. We believe that IoGen may also be useful
for the treatment and prevention of other types of excess cell growth
in female reproductive tissue, such as endometriosis, ovarian cysts
and pre-menopausal breast cancer.
Our efforts in infection control have resulted in one commercial
product to date. Launched in 1995, IodoZyme is a bovine teat sanitizer
sold through our marketing partner, West Agro, Inc.
In the future, Symbollon intends to investigate the potential effectiveness
of its technology in such antimicrobial applications as dermatology,
oral care, urinary tract infection and wound care.
|
